Skip to content

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04538885
Enrollment
50
Registered
2020-09-04
Start date
2020-09-10
Completion date
2021-05-30
Last updated
2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision

Brief summary

Poor incision healing is a common complication after abdominal surgery, mainly manifested as incision dehiscence, subcutaneous fat liquefaction, malnutrition, and incision infection. Poor healing of the incision will increase the patient's pain and prolong the patient's hospital stay, and the choice of wound treatment is closely related to the wound healing effect. Mesenchymal stem cells mainly rely on paracrine effects to exert their therapeutic effects and obtain better therapeutic effects in wound healing. Here, the pleiotropic factors secreted from mesenchymal stem cells (MSCs-PFs) will be used to treat patients with poor healing after surgery to evaluate its effectiveness and safety.

Interventions

BIOLOGICALThe pleiotropic factor derived from mesenchymal stem cells

The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.

Sponsors

Gansu Provincial Maternal and Child Health Care Hospital
CollaboratorOTHER
Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Wound size \<10X10cm2, the wound base only involves subcutaneous and muscle tissue; 2. Underwent surgical treatment, all incisions were type I, and the incisions healed poorly and delayed healing after 1 week; 3. There is inflammatory reaction at the incision, but no clear indication of infection, or severe infection of the incision.After debridement and dressing change, the infection is controlled and the fresh granulation period is entered 4. Men or women older than 17 years old and younger than 75 years old; 5. Psychologically stable, able to complete the test process.

Exclusion criteria

1. Wound size\>10X10cm2, the wound base is as deep as the chest and abdominal cavity, causing infection or osteomyelitis in the chest and abdominal cavity; 2. Surgical incision with purulent infection, local purulent secretions can be seen; 3. Those with obvious body temperature and white blood cell elevation, local purulent secretions have positive bacterial culture; 4. Patients with diabetes; 5. Glucocorticoid users; 6. Patients with immune dermatosis; 7. Neoplastic wounds, such as wounds after skin cancer resection, or skin wounds caused by tumor invasion; 8. Psycho-psychological disorders and poor compliance.

Design outcomes

Primary

MeasureTime frameDescription
Wound healing time and healing rate1 monthJudgment criteria for incision recovery (4 weeks after treatment): Cure: the patient's incision is completely or basically healed, and the surrounding skin returns to normal; markedly effective: the patient's incision is recovered\> 1/2, and the surrounding skin returns to normal; effective: the patient's incision is recovered \<1 /2, and the surrounding skin returned to normal; invalid: the patient's incision had no obvious changes, and the surrounding skin color had no obvious improvement.

Contacts

Primary ContactMeirong Li, doctor
meirong811225@126.com010-66936345

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026